<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE313nnn/GSE313248/</Other><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE313nnn/GSE313248/suppl/GSE313248_seurat_object.RDS</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313248</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Characterization of Circulating Neoantigen-Specific T Cell Responses and Their Public TCR Repertoires in Lynch Syndrome Carriers (scRNAseq)</name><description>Lynch syndrome (LS), a common hereditary cancer syndrome, provides a unique model to study immune surveillance at the earliest stages of tumorigenesis. A hallmark of LS carcinogenesis is the generation of highly immunogenic mutated neoantigens derived from insertion deletions, yet the transcriptomic states of the neoantigen-specific T cells that recognize them remain poorly characterized. Here, we characterized neoantigen-specific T cells from LS carriers using functional assays, single-cell RNA/TCR sequencing, and repertoire integration with existing data sets. Recurrent neoantigens elicited strong immune responses, with neoantigen-specific T cells mediating cytotoxicity against patient-derived tumor organoids. Single-cell analysis revealed oligoclonal expansions spanning effector and memory states with LS cancer survivors showing enrichment for metabolically exhausted subsets and previvor LS carriers retaining polyfunctional effectors. Cross-cohort analyses identified public clonotypes overlapping with tumor-infiltrating repertoire. These findings define the architecture of circulating neoantigen-specific immunity in LS and identify public TCRs as biomarkers for immune monitoring and immunoprevention.</description><dates><publication>2026/08/13</publication></dates><accession>GSE313248</accession><cross_references><GSM>GSM9364658</GSM><GSM>GSM9364647</GSM><GSM>GSM9364659</GSM><GSM>GSM9364648</GSM><GSM>GSM9364649</GSM><GSM>GSM9364660</GSM><GSM>GSM9364654</GSM><GSM>GSM9364655</GSM><GSM>GSM9364656</GSM><GSM>GSM9364657</GSM><GSM>GSM9364650</GSM><GSM>GSM9364651</GSM><GSM>GSM9364652</GSM><GSM>GSM9364653</GSM><GPL>21290</GPL><GSE>313248</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>